These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9381727)

  • 1. [Problems in evaluating the long-term effect of antihypertensive drugs: once again: the trough/peak ratio].
    Hitzenberger G
    Wien Med Wochenschr; 1997; 147(14):333-5. PubMed ID: 9381727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA guidelines on trough: peak ratios in the evaluation of antihypertensive agents. United States Food and Drug Administration.
    Meredith PA; Elliott HL
    J Cardiovasc Pharmacol; 1994; 23 Suppl 5():S26-30. PubMed ID: 7609502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical relevance of the 24-hour trough: peak ratio of antihypertensive drugs.
    Zannad F
    J Hypertens Suppl; 1995 Aug; 13(2):S109-12. PubMed ID: 8576780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amlodipine; clinical relevance of a unique pharmacokinetic profile.
    Meredith PA; Elliott HL
    J Cardiovasc Pharmacol; 1993; 22 Suppl A():S6-8. PubMed ID: 7522286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the smoothness index, the trough : peak ratio and the morning : evening ratio in assessing the features of the antihypertensive drug effect.
    Stergiou GS; Efstathiou SP; Skeva II; Baibas NM; Roussias LG; Mountokalakis TD
    J Hypertens; 2003 May; 21(5):913-20. PubMed ID: 12714865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The trough/peak ratio].
    Salvetti A; Virdis A
    Ann Ital Med Int; 1995 Oct; 10 Suppl():91S-95S. PubMed ID: 8562276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trough: peak ratio: the rationale behind the United States Food and Drug Administration recommendations.
    Lipicky RJ
    J Hypertens Suppl; 1994 Nov; 12(8):S17-8; discussion S18-9. PubMed ID: 7707150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of the long-term treatment with losartan and captopril and of the abrupt cessation on circadian blood pressure profile].
    Gorbunov VM; Savina LV; Metelitsa VI; Deev AD
    Eksp Klin Farmakol; 2001; 64(2):45-50. PubMed ID: 11548448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New FDA guidelines on the treatment of hypertension: comparison of different therapeutic classes according to trough/peak blood pressure responses.
    Meredith PA
    Arch Mal Coeur Vaiss; 1994 Nov; 87(11):1423-9. PubMed ID: 7771888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive effect of drugs: statistical distribution of the trough-to-peak ratio.
    Chi VX; Chau NP
    Biometrics; 1996 Mar; 52(1):286-90. PubMed ID: 8934597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The trough-to-peak ratio in the evaluation of an antihypertensive drug].
    Mancia G; Salvetti A
    G Ital Cardiol; 1994 Aug; 24(8):1043-8. PubMed ID: 7958635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive treatment and trough: peak ratio: general considerations.
    Meredith PA; Elliott HL
    J Hypertens Suppl; 1994 Nov; 12(8):S79-82; discussion S83. PubMed ID: 7707161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-measurement of blood pressure at home to evaluate drug effects by the trough: peak ratio.
    Ménard J; Chatellier G; Day M; Vaur L
    J Hypertens Suppl; 1994 Nov; 12(8):S21-5. PubMed ID: 7707151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of trough:peak ratio and the assessment of anti-hypertensive drug action.
    Elliott HL; Meredith PA
    J Hum Hypertens; 1995 Jun; 9(6):423-7. PubMed ID: 7473522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [How relevant is the trough-to peak ratio?].
    Ferrari P
    Schweiz Med Wochenschr; 2000 Mar; 130(9):329-35. PubMed ID: 10746273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What are the approaches for evaluating antihypertensive treatment by 24 h ambulatory blood pressure monitoring?
    Neutel JM; Smith DH; Weber MA
    Blood Press Monit; 1999; 4 Suppl 2():S23-8. PubMed ID: 10822419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The rationale for drug combinations in the therapy of arterial hypertension].
    Salvetti A; Virdis A; Di Venanzio L
    Ann Ital Med Int; 1993 Oct; 8 Suppl():107S-110S. PubMed ID: 8117517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension.
    Gradman AH; Traub D
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S22-30. PubMed ID: 17401313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
    Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of once-daily antihypertensive therapy.
    Myers MG
    Heart Dis; 2000; 2(2):S7-12. PubMed ID: 11728257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.